Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer

Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer. Ignatiadis, M.; Zardavas, D.; Lemort, M.; Wilke, C.; Vanderbeeken, M. C.; D'Hondt, V.; De Azambuja, E.; Gombos, A.; Lebrun, F.; Dal Lago, L.; Bustin, F.; Maetens, M.; Ameye, L.; Veys, I.; Michiels, S.; Paesmans, M.; Larsimont, D.; Sotiriou, C.; Nogaret, J. M.; Piccart, M.; Awada, A.. PLoS ONE. 2016; e0154009: p.e0154009. doi:10.1371/journal.pone.0154009 10.1371/journal.pone.0154009. eCollection 2016.

Article